Light Therapy for Obsessive-compulsive Disorder (OCD)
For patients and families
In plain language
An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.
- What is being studied
- The protocol lists: Light therapy.
- Who it may be relevant to
- Registry conditions: OCD. Basic parameters: 17 years — 35 years · All.
- What needs checking
- Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
- Where it takes place
- United States
- Next step
- Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →
Unsure about the terms? Read our patient guide →
Official title
Light Therapy for Obsessive-compulsive Disorder: A Circadian Medicine Approach
Overview
The goal of this clinical trial is to test whether light therapy is effective for reducing symptoms in young adults with OCD and late bedtimes (1am or later). The main question\[s\] it aims to answer are: Does light therapy reduce OCD symptoms? Does light therapy advance the circadian clock? If there is a comparison group: Researchers will compare a higher dose of light therapy to a lower dose to see if dose amount affects symptom reduction. Participants will asked to: 1. Wear light therapy glasses for 1 hour each morning and complete a daily light therapy log for 5 weeks 2. Track their sleep every day with a wearable monitor and an electronic sleep diary for 5 weeks 3. Complete a 1-time assessment of sensitivity to light exposure 4. Complete self-report measures of OCD 4 times/day at baseline (2 weeks), mid-treatment (1 week), and end of treatment (1 week)
Interventions
- Behavioral Light therapy
5 weeks of light therapy administered via wearable light therapy glasses worn for 1 hour each morning after awakening.
Primary outcome measures
- Yale Brown Obsessive-Compulsive Scale (YBOCS) [Time frame: Administered at baseline, in treatment week 3, and post-treatment (3 administrations over 7 weeks)]
- Daily Perseverative Thinking Questionnaire [Time frame: Administered 4 times/day for 2 weeks at baseline, 4 times/day for 1 week in treatment week 3, and 4 times/day for 1 week in treatment week 5]
Secondary outcome measures (1)
- Circadian melatonin phase [Time frame: At baseline and post-treatment (after 5 weeks of treament)]
Eligibility criteria
Inclusion criteria
- Primary DSM-5 OCD diagnosis
- Bedtime 0100 or later
- Age 18-35
- English speaking
Exclusion criteria
- Subjects must not be currently participating in another research study that would influence their participation in our study.
- Diagnostic status
- Treatment status
- Night shift work or travel more than 1 time zone outside of Central Standard Time (CST) in the past month
- Pregnancy status
- Medication status
- Regular nicotine or marijuana use
Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.
Healthy volunteers: Yes
Study design
- Allocation
- Randomized
- Model
- Parallel assignment
- Masking
- Double blind
- Primary purpose
- Treatment
Study locations
United States · 1 center
- Washington University — St Louis
Identifiers
NCT: NCT06720090 · K23MH137376